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Edited by Jesus AvilaAbstract b-Amyloid precursor protein (APP) is a type I
transmembrane protein. Its cleavages by b- and c-secretases
yield b-amyloid, which is the main constituent of senile plaques
in Alzheimer’s disease (AD). In apoptotic cells and AD brains,
APP is alternatively cleaved by caspases in the cytoplasmic
region after the Asp664 residue (with respect to the numbering
conversion for the APP695 isoform). Caspase-cleaved frag-
ments of APP are cytotoxic and have been implicated in AD
pathogenesis; however, the mechanisms regulating the cleavage
have not been studied. APP is constitutively phosphorylated at
Thr668 in brain. In the present study, we demonstrate that
APP phosphorylated at Thr668 is less vulnerable to cytoplas-
mic cleavage by caspase-3 and caspase-8. This suggests that
APP phosphorylation suppresses the generation of caspase-
cleaved fragments of APP in the brain and that perturbation
of this phosphorylation may be involved in APP-mediated
neurotoxicity.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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b-Amyloid precursor protein (APP) is a ubiquitously ex-
pressed transmembrane protein and is the precursor of b-am-
yloid peptide (Ab), which is a principal component of senile
plaques. Ab is hypothesized to induce neuronal toxicity and is
implicated in Alzheimer’s disease (AD) pathogenesis [1]. In-
dependently of the cleavages that produce Ab, APP is also
cleaved by caspases between Asp664 and Ala665 (numbering
for the APP695 isoform) in its cytoplasmic domain (APPcyt)
to generate a short cytoplasmic fragment composed of 31
amino acid residues, APP665-695 (termed C31), and a large
amino-terminal protein that lacks the 31 residues (termed
APPDC31) [2–5] (see Fig. 1). These caspase-cleaved fragments
of APP have been observed in the brains of AD patients but
not in controls, implicating this cleavage in AD pathogenesis* Corresponding author. Fax: +81-11-706-4991.
E-mail address: tsuzuki@pharm.hokudai.ac.jp (T. Suzuki).
Abbreviations: Ab, b-amyloid peptide; AD, Alzheimer’s disease; APP,
b-amyloid precursor protein; APPcyt, the cytoplasmic domain of APP;
Cdk5, cyclin-dependent kinase 5; GST, glutathione S-transferase;
JNK, c-jun N-terminal kinase; PS, presenilin
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although the molecular mechanism has not been elucidated
[5–8]. APPDC31 has also been reported to induce neuronal cell
death [9] and the controversial possibility that caspase-induced
cleavage of APP increases Ab generation has also been pro-
posed [2,7,10,11].
The APPcyt is phosphorylated at Thr668 in vivo speciﬁcally
in the brain [12]. Cyclin-dependent kinase 5 (Cdk5), a unique
member of the Cdk family that is implicated in central nervous
system development, participates in this phosphorylation [12].
In cultured cells, APP is also phosphorylated at Thr668 by c-
jun N-terminal kinase (JNK), which is a major kinase in signal
transduction for cell death and/or cell survival during the
cellular stress response [13–16], and by cdc2 kinase during the
G2/M phase of the cell cycle [17]. The phosphorylation at
Thr668 induces a conformational change of the Thr668–
Pro669 bond and alters the overall structure of the cytoplasmic
domain to aﬀect the interaction of APP with its binding pro-
teins, such as FE65 [18,19]. Functionally, APP phosphoryla-
tion at Thr668 has been associated with neuronal outgrowth,
Ab generation, and APP-associated transcriptional regulation,
however, the roles of the phosphorylation in these processes
are not fully understood ([20–22], Nakaya, T., Kawaguchi, E.,
Shigenaga, K., Yoshida, T. and Suzuki, T, manuscript in
preparation).
Although involvement of protein phosphorylation in pro-
teolysis has not yet been widely studied, there are several
proteins whose susceptibility to proteolysis is inhibited or at-
tenuated by phosphorylation near the proteolytic cleavage site
[23]. Because caspase cleavage of APP occurs near the phos-
phorylation site (see Fig. 1), in the present study we investi-
gated the relationship between APP phosphorylation and
caspase cleavage, and found that caspase cleavage of APP is
attenuated by its phosphorylation at Thr668.2. Materials and methods
2.1. Antibodies and peptides
The polyclonal anti-phosphoAPP antibody UT-33 [19,24], which
selectively recognizes APP phosphorylated at the Thr668 residue, and
an end-speciﬁc antibody against APPDC31 SAC [9] have been de-
scribed. The polyclonal anti-APP cytoplasmic domain A8717 (Sigma),
the polyclonal anti-phospho-APP Thr668 (anti-PAPP; Cell Signaling
Tech.) and the monoclonal anti-FLAG M2 (Sigma) antibodies were
purchased. Peptides encompassing residues 649–695 of APP695 (with
or without a phosphate at Thr668) were chemically synthesized and
puriﬁed [19].blished by Elsevier B.V. All rights reserved.
Fig. 2. The APPcyt is cleaved less by caspase-3 in vitro when phos-
phorylated by Cdk5. Puriﬁed GST–APPcyt was subjected to in vitro
phosphorylation by an active complex of recombinant p25/Cdk5 in the
presence (+) or absence ()) of ATP. The phosphorylated and non-
phosphorylated forms were incubated with (+) or without ()) caspase-3
and analyzed by immunoblotting with A8717 to detect intact GST–
APPcyt (ﬁrst panel) and C31 (second panel) and with UT-33 to detect
intact GST–APPcyt phosphorylated at Thr668 (GST–P–APPcyt; third
panel) and phosphorylated C31 (P-C31; fourth panel).
Fig. 1. Schematic representation of APP and the amino acid sequence
of the APPcyt. Sites cleaved by caspase and phosphorylated by Cdk5
and JNK, and the extent of the caspase-cleaved fragments APPDC31
and C31 are indicated. The regions recognized by the antibodies used in
this study (anti-FLAGM2, anti-APP cytoplasmic domain A8717, anti-
caspase-cleaved fragment of APP SAC, and anti-phosphoAPP UT-33
and PAPP antibodies) are also indicated. The amino acids are num-
bered according to the APP695 isoform. TM, transmembrane domain.
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Glutathione S-transferase (GST)–APPcyt was produced in Esche-
richia coli BL21 transformed with pGEX-4T-1-APPcyt and puriﬁed
using glutathione–Sepharose 4B (Amersham Biosciences) as described
[25,26]. Puriﬁed GST–APPcyt was incubated with recombinant Cdk5
in a complex with its activator p25 for 2 h at 30 C in 30 mM MOPS
[pH 7.2] 5 mM MgCl2 containing or not containing 100 lM ATP.
2.3. In vitro cleavage of APP by caspases
Puriﬁed APP proteins or peptides were incubated with caspase-3 or
caspase-8 (BIOMOL Research Laboratories) in caspase reaction buﬀer
(50 mMHEPES [pH 7.4], 10% [v/v] glycerol, 100 mMNaCl, 0.1% [w/v]
CHAPS, 1 mM EDTA, 10 mM DTT, and 1 lM Microcystin-LR) for
4 h at 30 C. The samples were separated by SDS–PAGE and analyzed
by immunoblotting using an ECL detection kit (Amersham Bio-
sciences) or Coomassie brilliant blue R250 staining. Quantiﬁcation was
performed with VersaDoc imaging system using Quantity One soft-
ware (BioRad) or with the Scion Images software program (Scion
Corp.), which was calibrated by serial dilution.
2.4. Cell culture and protein puriﬁcation
Human embryonic kidney 293 (HEK293) cells stably expressing
human APP695 or APP695 T668A tagged with FLAG at the amino-
terminal were generated and cultured as described [25]. Cells were
treated with or without a combination of 0.5 M sorbitol and 2 lM
staurosporine (Sigma) in the presence or absence of 50 lMZ-Val–Ala–
Asp(OMe)–FMK (Z-VAD; BIOMOL) for 2 h in culture medium. The
cells were collected and lysed in radioimmunoprecipitation (RIPA)
buﬀer (50 mM Tris–HCl (pH 8.0), 0.1% [w/v] SDS, 0.5% [w/v] sodium
deoxycholate, 1% [v/v] Nonidet P-40, and 0.15 M NaCl) containing
5 lg/ml chymostatin, 5 lg/ml leupeptin, 5 lg/ml pepstatin A, and 1 lM
Microcystin-LR, and subjected to immunoblot analysis [26]. To purify
FLAG-APP, HEK293 cells stably expressing FLAG-APP695 were
treated with or without 0.5 M sorbitol for 1.5 h. Cell lysates were
subjected to immunoprecipitation with anti-FLAG M2 aﬃnity gel
(Sigma). Proteins were eluted with 100 lg/ml FLAG peptide (Sigma) in
50 mM HEPES [pH 7.4], 100 mM NaCl and 1 lM Microcystin-LR
and concentrated using a Microcon YM-30 column (Millipore).3. Results
3.1. The APPcyt is less vulnerable to caspase-induced cleavage
when phosphorylated at Thr668
The eﬀect of APP phosphorylation at Thr668 on the caspase
cleavage of APP was examined in vitro using the APPcyt and
recombinant caspase-3, which has been reported to be thepredominant caspase involved in APP cleavage (Fig. 1) [2]. We
executed caspase-induced cleavage of APPcyt, which was
phosphorylated by Cdk5 in vitro (Fig. 2). In the presence of
ATP, a portion of APPcyt was phosphorylated at Thr668 as
detected by an anti-phosphoAPP antibody (third panel). In-
cubation with recombinant caspase-3 decreased the amount of
intact GST–APPcyt (ﬁrst panel) and generated the carboxyl-
terminal fragment C31 as detected by an antibody against the
carboxyl-terminal region of APP (second panel). GST–APPcyt
subjected to phosphorylation (ATP +) yielded C31 less eﬃ-
ciently than GST–APPcyt not subjected to phosphorylation
(ATP )). C31 phosphorylated at Thr668 was also generated
from phosphorylated GST–APPcyt, however, the amount was
too small to be clearly detected (fourth panel). The rate of
phosphorylated C31 (fourth panel) to phosphorylated GST–
APPcyt (third panel) was much less than that of total C31
(second panel) to GST–APPcyt (ﬁrst panel). This result sug-
gests that phosphorylated APP is less vulnerable to the
cleavage by caspase-3.
We next examined the stoichiometry of the cleavage of APP
by caspase-3 using chemically synthesized peptides of the APP
cytoplasmic domain with or without phosphate at Thr668
residue. Treatment with caspase-3 dose-dependently decreased
the amount of intact APPcyt (Fig. 3A, arrowhead) and gen-
erated the cleaved fragment C31 (Fig. 3A, arrow). The amino-
terminal half of the cleaved fragment (APP649–664, see Fig. 1)
was not detected, probably because it was too small. Com-
pared with the non-phosphorylated peptides, phosphorylated
APPcyt was cleaved much less eﬃciently by caspase-3 (Fig. 3A
and B).
Caspase-3 was initially identiﬁed as the protease responsible
for the cleavage of APPcyt [2], but caspases-6, -8, and -9 have
also been reported to cleave APP between Asp664 and Ala665
[3–5]. Caspases are classiﬁed into three groups on the basis of
their substrate speciﬁcity; caspase-3 belongs to the group II
caspases, and caspases-6, -8, and -9 belong to group III [27].
To elucidate whether phosphorylation at Thr668 also attenu-
ates the cleavage by group III caspases, we examined the
cleavage of phosphorylated and non-phosphorylated APP by
caspase-8 (Fig. 3C). Phosphorylated APP was cleaved less ef-
ﬁciently by caspase-8 than non-phosphorylated APP, although
Fig. 3. Phosphorylation of APP at Thr668 prevents its cleavage by
caspase-3 and caspase-8. (A) and (C) Cleavage of the APPcyt peptide
with or without phosphate at Thr668 by caspase-3 and caspase-8.
Synthetic APPcyt-(649–695) peptides (0.5 nmol) with (P-APP) or
without (APP) a phosphate at Thr668 were incubated with caspase-3
(0, 2, 10, and 40 units in A, 50 units in C) or caspase-8 (50 units in C),
and the resulting fragments were detected with SDS–PAGE followed
by staining with Coomassie brilliant blue R250. (B) The amounts of
C31 (arrow in A) were quantiﬁed and are displayed as a ratio relative
to the level of APPcyt without caspase-3 (set to 1.0).
Fig. 4. APP695 phosphorylation at Thr668 induced by stress produces
fewer caspase-cleaved fragments. APP was isolated from HEK293 cells
stably expressing FLAG-APP695 following no treatment (indicated as
Con) or treatment with 0.5 M sorbitol (indicated as Srb) for 1.5 h.
Isolated APP was analyzed by immunoblotting with the anti-APP
cytoplasmic domain antibody A8717 (arrowheads in left panel, total
APP) and UT-33 (open arrowheads in middle panel, phosphorylated
APP). Isolated APP incubated with (+) or without ()) caspase-3 were
also analyzed by immunoblotting with A8717 (right panels). Intact
APP (arrowheads) and C31 (arrow) were indicated. Asterisk indicates
artiﬁcially digested product of APP in vitro. The numbers refer to the
molecular mass (kDa) of the protein standards.
Fig. 5. Thr668 residue of APP is involved in the regulation of caspase-
cleavage in cells. (A) HEK293 cells stably expressing FLAG-APP
(WT) or FLAG-APP T668A (T668A) were treated with or without a
combination of 0.5 M sorbitol and 2 lM staurosporine (stimulation) in
the presence or absence of 50 lM Z-VAD (inhibitor) for 2 h. Cell ly-
sates were analyzed by immunoblotting with SAC (upper panel), anti-
PAPP (middle panel) and M2 (lower panel) antibodies. (B) The
amounts of APPDC31 detected by SAC and total APP detected by M2
were quantiﬁed, and the ratio of APPDC31 to total APP was com-
pared. Average of experiments with seven independent cell lines either
expressing WT or T668A is displayed as a ratio relative to the mean of
the cell lines expressing WT (set to 1.0). Bars indicate the meansS.D.
(*P < 0:05).
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APPcyt and phospho-APPcyt was not as remarkable as that by
caspase-3.
3.2. Phosphorylation of APP695 at Thr668 attenuates its
caspase-induced cleavage
To further examine the role of APP phosphorylation in
caspase cleavage, we performed a cellular analysis. First, we
examined whether full-length APP phosphorylated at Thr668
in cells is less vulnerable to caspase-induced cleavage in vitro
(Fig. 4). Comparable amounts of full-length APP were isolated
from cells, which are stably expressing FLAG-tagged APP,
with or without treatment with hyperosmotic stress which in-
duces APP phosphorylation eﬀectively [14,16] (Fig. 4, left and
middle panels). Phosphorylation of APP at Thr668 was ob-
served in APP isolated from treated cells (open arrowheads in
middle panel), but not in APP from non-treated cells. Incu-
bation of the isolated APP with caspase-3 decreased the
amount of intact APP (arrowheads in upper right panel) and
generated the cleaved fragment C31 (arrow in lower right pa-
nel). Because in vitro caspase-3 artiﬁcially cleaves APP in the
extracellular domain in addition to the cleavage site in the
cytoplasmic domain [2], we compared the generation of C31
rather than the decrease of intact APP to estimate the eﬀect of
APP phosphorylation. The amount of C31 generated fromAPP isolated from phosphorylation-induced cells was smaller
than that from not induced cells. C31 phosphorylated at
Thr668 could not be detected by immunoblotting with the
anti-phosphoAPP antibody (data not shown). These suggest
that phosphorylation of full-length APP at Thr668 in human
cells attenuates the cleavage by caspases.
Finally, we examined whether Thr668 residue is actually
involved in caspase-induced cleavage of APP in cells. HEK293
cells stably expressing wild-type APP (WT) or APP carrying
Ala substitution for Thr668 (T668A) were treated with a
combination of sorbitol and staurosporine, an apoptosis in-
ducer (Fig. 5). APP WT was remarkably phosphorylated at
Thr668 after the stimulation (middle panel). APPDC31 was
observed after the stimulation using an endo-speciﬁc antibody
SAC, whereas it was not observed when cells were treated with
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dependent cleavage of APP was induced eﬀectively by the
stimulation in both cell lines (upper panel). However, com-
pared with cell lines expressing APP WT, cell lines expressing
APP T668A tended to produce signiﬁcantly larger amount of
APPDC31. T668A was not phosphorylated after the stimula-
tion as APP WT was (middle panel), whereas the sensitivity to
caspase cleavage in vitro of T668A is same as that of non-
phosphorylated APP WT as far as we examined (data not
shown). Therefore, this result suggests that the phosphoryla-
tion of APP at Thr668 can attenuate the caspase-induced
cleavage of APP in cell.4. Discussion
In this study, we demonstrated that APP phosphorylation at
the Thr668 residue attenuates caspase-induced cleavage of
APP after the Asp664 residue. Cleavage at this site generates
cytotoxic fragments and is implicated in AD pathogenesis [2–
9]. To our knowledge, this is the ﬁrst report concerning the
regulation of caspase-induced cleavage of APP.
Caspases are widely known to cleave protein substrates
during apoptotic cell death; however, the involvement of
phosphorylation of substrates in regulating this caspase-in-
duced cleavage has been demonstrated in only a few molecules,
including presenilin (PS) 1, PS2, Bid, MST1, and IjB [29–33].
PS1 and PS2 are causative factors of familial AD and are re-
sponsible for the c-cleavage of APP [1]. PS1 is cleaved between
Asp345 and Ser346 by caspase-3, and its phosphorylation at
Ser346 by PKC inhibits the cleavage [29]. PS2 is also cleaved
by caspase-3, between Asp329 and Ser330 and between Asp326
and Ser327, and phosphorylation of the Ser residues inhibits
the cleavage [30]. Phosphorylation of IjB and MST1 at Ser
residues located adjacent to caspase cleavage sites also pre-
vents cleavage [32,33]. Our results suggest that cleavage of
APP is also likely to be regulated by phosphorylation, al-
though APP is diﬀerent from these previously reported pro-
teins in that the phosphorylation occurs at a Thr residue
located several residues away from the cleavage site. Thr668 of
APP is located in the motif 667-VTPEER-672, which forms a
type I b-turn and an amino-terminal helix-capping box struc-
ture [18]. Phosphorylation of Thr668 induces signiﬁcant con-
formational changes in the cytoplasmic domain to aﬀect the
interaction of APP with its binding proteins [19]. Therefore, we
suppose that the prevention of caspase cleavage in APP may be
mediated by direct steric hindrance by the phosphate group
itself or by the conformational change induced by the phos-
phorylation.
In our cellular model, phosphorylation of APP was impli-
cated in suppressing caspase-induced APP cleavage. In brain,
APP is suggested to be phosphorylated by JNK under certain
stress conditions such as ischemia and injury as in cultured
cells, although it has not been well studied yet. In addition, a
portion of APP is constitutively phosphorylated by Cdk5
[12,22]. These constitutive and/or transient phosphorylation
may lower the risk of cytotoxicity in neurons by reducing the
generation of C31 or APPDC31. Phosphorylation of PS1, PS2,
and Bid is thought to reduce the progression of apoptosis by
suppressing their caspase-induced cleavage [28–30], and the
regulation of caspase-induced protein cleavage by phosphor-ylation might therefore be a widely used mechanism for reg-
ulating cell death.
Caspase-induced cleavage of APP is implicated in AD
progression. Higher expression of activated caspases is ob-
served in the brains of patients with AD than in age-mat-
ched controls [2,5]. Moreover, caspase-cleaved products of
APP are detectable in AD brains but not in controls [2,5,6].
Lu et al. [8] proposed that Ab-induced cell death is associ-
ated with the caspase cleavage of APP. These observations
suggest that the cytotoxicity of caspase-cleaved products of
APP could contribute to the neurodegeneration of AD that
is triggered by the abnormal generation and accumulation of
Ab. Although the role of APP phosphorylation in AD
progression has not been well characterized, a recent report
suggested that Thr668-phosphorylated APP is present in
high levels and accumulates in some cellular structures in the
AD brain [22]. Therefore, APP phosphorylation may de-
crease the toxicity induced by caspase-dependent cleavage.
Conversely, neurodegeneration in AD pathogenesis might be
accelerated in neurons in which APP phosphorylation is
perturbed. Further elucidation of mechanisms regulating the
phosphorylation of APP and detailed proﬁling of the rela-
tionship between phosphorylated APP and caspase-cleaved
APP in the AD brain may contribute to understanding the
neuronal degeneration process and may help to identify
novel therapeutic targets for the treatment of AD.Acknowledgements: We are grateful to Dr. S. Gandy (Thomas Jeﬀer-
son University) for the G369 antibody and to Drs. A.C. Nairn (Yale
University), Y. Kim and P. Greengard (Rockefeller University) for
recombinant p25/Cdk5. This work was supported in part by Grant-in-
Aid for Scientiﬁc Research on Priority Areas-Advanced Brain Science
Project TS16015201 from the Ministry of Education, Science, Culture,
Sports, and Science and Technology, Japan.References
[1] Hardy, J. and Selkoe, D.J. (2002) Science 297, 353–356.
[2] Gervais, F.G., Xu, D., Robertson, G.S., Vaillancourt, J.P., Zhu,
Y., Huang, J., LeBlanc, A., Smith, D., Rigby, M., Shearman,
M.S., Clarke, E.E., Zheng, H., Van Der Ploeg, L.H., Ruﬀolo,
S.C., Thornberry, N.A., Xanthoudakis, S., Zamboni, R.J., Roy, S.
and Nicholson, D.W. (1999) Cell 97, 395–406.
[3] Pellegrini, L., Passer, B.J., Tabaton, M., Ganjei, J.K. and
D’Adamio, L. (1999) J. Biol. Chem. 274, 21011–21016.
[4] Weidemann, A., Paliga, K., Durrwang, U., Reinhard, F.B.,
Schuckert, O., Evin, G. and Masters, C.L. (1999) J. Biol. Chem.
274, 5823–5829.
[5] Lu, D.C., Rabizadeh, S., Chandra, S., Shayya, R.F., Ellerby,
L.M., Ye, X., Salvesen, G.S., Koo, E.H. and Bredesen, D.E.
(2000) Nat. Med. 6, 397–404.
[6] Galvan, V., Chen, S., Lu, D., Logvinova, A., Goldsmith, P., Koo,
E.H. and Bredesen, D.E. (2002) J. Neurochem. 82, 283–294.
[7] Dumanchin-Njock, C., Alves da Costa, C.A., Mercken, L.,
Pradier, L. and Checler, F. (2001) J. Neurochem. 78, 1153–1161.
[8] Lu, D.C., Soriano, S., Bredesen, D.E. and Koo, E.H. (2003) J.
Neurochem. 87, 733–741.
[9] Nishimura, I., Uetsuki, T., Kuwako, K., Hara, T., Kawakami, T.,
Aimoto, S. and Yoshikawa, K. (2002) Cell Death Diﬀer. 9, 199–
208.
[10] Soriano, S., Lu, D.C., Chandra, S., Pietrzik, C.U. and Koo, E.H.
(2001) J. Biol. Chem. 276, 29045–29050.
[11] Tesco, G., Koh, Y.H. and Tanzi, R.E. (2003) J. Biol. Chem. 278,
46074–46080.
[12] Iijima, K., Ando, K., Takeda, S., Satoh, Y., Seki, T., Itohara, S.,
Greengard, P., Kirino, Y., Nairn, A.C. and Suzuki, T. (2000) J.
Neurochem. 75, 1085–1091.
252 H. Taru et al. / FEBS Letters 567 (2004) 248–252[13] Standen, C.L., Brownlees, J., Grierson, A.J, Kesavapany, S., Lau,
K.F., McLoughlin, D.M. and Miller, C.C. (2001) J. Neurochem.
76, 316–320.
[14] Inomata, H., Nakamura, Y., Hayakawa, A., Takata, H., Suzuki,
T., Miyazawa, K. and Kitamura, N. (2003) J. Biol. Chem. 278,
22946–22955.
[15] Scheinfeld, M.H., Ghersi, E., Davies, P. and D’Adamio, L. (2003)
J. Biol. Chem. 278, 42058–42063.
[16] Taru, H. and Suzuki, T. (2004) J. Biol. Chem. 279, 21628–21636.
[17] Suzuki, T., Oishi, M., Marshak, D.R., Czernik, A.J., Nairn, A.C.
and Greengard, P. (1994) EMBO J. 13, 1114–1122.
[18] Ramelot, T.A. and Nicholson, L.K. (2001) J. Mol. Biol. 307, 871–
884.
[19] Ando, K., Iijima, K., Elliott, J.I., Kirino, Y. and Suzuki, T. (2001)
J. Biol. Chem. 276, 40353–40361.
[20] Ando, K., Oishi, M., Takeda, S., Iijima, K., Isohara, T., Nairn,
A.C., Kirino, Y., Greengard, P. and Suzuki, T. (1999) J. Neurosci.
19, 4421–4427.
[21] Liu, F., Su, Y., Li, B., Zhou, Y., Ryder, J., Gonzalez-DeWhitt, P.,
May, P.C. and Ni, B. (2003) FEBS Lett. 547, 193–196.
[22] Lee, M.S., Kao, S.C., Lemere, C.A., Xia, W., Tseng, H.C., Zhou,
Y., Neve, R., Ahlijanian, M.K. and Tsai, L.H. (2003) J. Cell Biol.
163, 83–95.
[23] Tozser, J., Bagossi, P., Zahuczky, G., Specht, S.I, Majerova, E.
and Copeland, T.D. (2003) Biochem. J. 372, 137–143.[24] Taru, H., Iijima, K., Hase, M., Kirino, Y., Yagi, Y. and Suzuki,
T. (2002) J. Biol. Chem. 277, 20070–20078.
[25] Tomita, S., Ozaki, T., Taru, H., Oguchi, S., Takeda, S., Yagi, Y.,
Sakiyama, S., Kirino, Y. and Suzuki, T. (1999) J. Biol. Chem. 274,
2243–2254.
[26] Taru, H., Kirino, Y. and Suzuki, T. (2002) J. Biol. Chem. 277,
27567–27574.
[27] Thornberry, N.A., Rano, T.A., Peterson, E.P., Rasper,
D.M., Timkey, T., Garcia-Calvo, M., Houtzager, V.M.,
Nordstrom, P.A., Roy, S., Vaillancourt, J.P., Chapman,
K.T. and Nicholson, D.W. (1997) J. Biol. Chem. 272, 17907
–17911.
[28] Bilney, A.J. and Murray, A.W. (1998) FEBS Lett. 424, 221–
224.
[29] Fluhrer, R., Friedlein, A., Haass, C. and Walter, J. (2004) J. Biol.
Chem. 279, 1585–1593.
[30] Walter, J., Schindzielorz, A., Grunberg, J. and Haass, C. (1999)
Proc. Natl. Acad. Sci. USA 96, 1391–1396.
[31] Desagher, S., Osen-Sand, A., Montessuit, S., Magnenat, E.,
Vilbois, F., Hochmann, A., Journot, L., Antonsson, B. and
Martinou, J.C. (2001) Mol. Cell 8, 601–611.
[32] Graves, J.D., Draves, K.E., Gotoh, Y., Krebs, E.G. and Clark,
E.A. (2001) J. Biol. Chem. 276, 14909–14915.
[33] Barkett, M., Xue, D., Horvitz, H.R. and Gilmore, T.D. (1997) J.
Biol. Chem. 272, 29419–29422.
